Last reviewed · How we verify
DFMO
At a glance
| Generic name | DFMO |
|---|---|
| Also known as | Difluoromethylornithine, Eflornithine, α-difluoromethylornithine, difluoromethyl ornithine monohydrochloride, iWilfin, D,L-ɑdifluoromethylornithine |
| Sponsor | Aminex Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (PHASE1, PHASE2)
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (PHASE1, PHASE2)
- Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) (PHASE1, PHASE2)
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma (PHASE2)
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas (PHASE1, PHASE2)
- An Intermediate Expanded Use Trial of DFMO
- Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PHASE2)
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFMO CI brief — competitive landscape report
- DFMO updates RSS · CI watch RSS
- Aminex Therapeutics, Inc. portfolio CI